COUR Pharmaceuticals

Executive Summary

COUR Pharmaceuticals is a clinical-stage biotechnology company pioneering antigen-specific immune tolerance therapies for autoimmune diseases using its proprietary nanoparticle platform. The platform delivers disease-specific antigens encapsulated in biodegradable nanoparticles, designed to reprogram the immune system to restore self-tolerance without broad immunosuppression. The company's pipeline targets several autoimmune conditions with high unmet need, including primary biliary cholangitis (PBC), type 1 diabetes (T1D), myasthenia gravis (MG), and celiac disease. By addressing the root cause of autoimmunity, COUR's approach has the potential to offer durable disease modification with improved safety profiles compared to standard-of-care immunosuppressants. The company is privately held and has not disclosed its financial details or stage of clinical development for specific programs. As a platform-based biotech, its success hinges on positive proof-of-concept data in lead indications and its ability to expand into additional autoimmune diseases through partnerships or internal development.

Upcoming Catalysts (preview)

• H2 2026Phase 2 data readout for primary biliary cholangitis (PBC)40% success
• 2026Initiation of Phase 2 trial for type 1 diabetes (T1D)60% success
• 2026Partnership or licensing deal for celiac disease program30% success